Kuwait’s ‘Visionary Lighthouse’ Pavilion Illuminates Expo 2025 Osaka with Innovative Design and a Future-Driven Vision
The Kuwait Pavilion at Expo 2025 Osaka, Kansai, Japan, officially opened its doors today, unveiling a spectacular architectural landmark that embodies the country’s bold vision for the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422295094/en/
The Kuwait Pavilion at Expo 2025 Osaka (Photo: AETOSWire)
Designed as a “Visionary Lighthouse”, the pavilion stands as a dynamic symbol of the ambitious national development plan, New Kuwait 2035, seamlessly integrating the nation’s rich heritage, innovation, and sustainability in a transformative visitor experience that engages audiences from around the world.
Located in the “Empowering Lives” district, the pavilion’s design draws inspiration from Kuwait’s maritime and desert landscapes, reflecting the nation’s journey of resilience, progress, and forward-looking spirit.
Kuwait’s participation in Expo 2025 Osaka highlights the continuation of a long-standing relationship between Kuwait and Japan, built on economic collaboration, cultural exchange, and mutual respect. Having first participated in Expo Osaka in 1970, Kuwait returns 55 years later with a pavilion that emphasises the country’s expanding influence in regional and international development.
Salem Al-Watyan, Commissioner General of the State of Kuwait Pavilion at Expo 2025 Osaka, said: "Our presence at Expo 2025 Osaka is a testament to Kuwait’s enduring friendship with Japan. The pavilion reflects our rich heritage and our commitment to shaping a sustainable and innovative future, highlighting Kuwait’s vision as a leader in global collaboration."
Dr. Naser Al Daihani, Director of the State of Kuwait Pavilion at Expo 2025 Osaka, said: "This pavilion captures Kuwait’s ambition and resilience, offering visitors a unique journey connecting the past and the future. As we celebrate our participation in this global event, we look forward to fostering new partnerships and further enhancing Kuwait’s global presence and influence."
Complementing the architecture, the pavilion’s visual identity draws from the natural elements of Kuwait.
The pavilion’s interactive and immersive interior invites visitors on a multi-sensory journey through Kuwait’s rich past and its bold aspirations for a sustainable, innovative, and technology-driven future. Through storytelling and exhibits, the experience highlights Kuwait’s commitment to empowering lives through progress, knowledge, and collaboration.
The Pavilion's bold, open design blends seamlessly into the public realm while making a strong visual impact.
The pavilion’s inauguration featured the spectacular Pearl Lighting Show, an evocative tribute to Kuwait’s maritime heritage and future aspirations.
The Kuwait Pavilion promises to be one of the most compelling attractions at Expo 2025 Osaka.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422295094/en/
Contacts
Cristian Lanzanova
Abra Consulting
Dubai, UAE
cristian@abraconsult.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press Release
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly
Traxys Group and the Shareholders of Comax2 AB - the holding company of Carbomax AB - sign Share Purchase Agreement to sell 100% interests to Traxys Group12.1.2026 19:20:00 CET | Press Release
Traxys S.à.r.l., Investment Aktiebolaget Spiltan and other major shareholders of Comax 2 AB – the holding company of Carbomax AB –are pleased to announce that they have signed a Share Purchase Agreement (SPA) to sell 100% interests to Traxys Group. Carbomax AB is a leading Swedish trading house and industrial operator specializing in ferroalloys, carbon products and briquettes. The transaction aims to strengthen Traxys’ presence in the Scandinavian market and support the region’s transition toward sustainable steel production. Closing of the transaction is expected to occur in the first quarter 2026 following clearance by Swedish authorities, including foreign direct investment and antitrust approvals. Carbomax serves regional steel plants and most of foundries across the Nordics. With its strategic location near Västerås harbor and integrated processing capabilities Carbomax is well-positioned to capitalize on growing demand for green steel and sustainable raw materials. Mark Kristoff
Lenovo Brings Real-Time Store Visibility and AI-Driven Support to Retail—Delivering Value on Day One12.1.2026 19:00:00 CET | Press Release
Retailers lose revenue every time an online store goes down, a system fails, or frontline employees lack the tools to act in the moment. Meanwhile, generative AI platforms and AI agents are creating new opportunities to increase online retail experiences and conversion rates. Yet while AI has the potential to help retailers drive better margins and competitive advantage, many still find it challenging to translate experimentation into consistent, day-to-day operational and revenue improvements. Today at NRF: Retail’s Big Show, Lenovo announced their latest AI-powered solutions - Smart Store Services and AI Retail Assistants - designed to deliver immediate, measurable value for retailers. Supported by Lenovo Hybrid AI Services, the solutions embed AI directly into daily retail operations, helping retailers prevent disruptions before revenue is lost, support associates in real time, and scale AI into repeatable performance across physical and digital stores. “Retail leaders don’t invest
Owkin Brings Biology Super Intelligence Closer to Reality with New AI Infrastructure for Biological Breakthroughs12.1.2026 18:00:00 CET | Press Release
Owkin, the AI company on a mission to solve the complexity of biology, today announced the launch of its agentic infrastructure for biology, making its best-in-class AI agents available to the healthcare ecosystem. The announcement comes at the JPM Healthcare Conference 2026 and follows Owkin’s recent strategic partnerships and its just-announced integration with Claude for Healthcare and Life Sciences by Anthropic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112461277/en/ Owkin, a 10-year-old AI company with $300 million in funding, is introducing the infrastructure, built on a unique advantage: unparalleled, curated, multimodal patient data from diverse geographies, collected from more than 800 hospitals over a decade. While other companies focus primarily on data derived from laboratory research, Owkin's patient data-trained AI agents enable comprehensive and clinically relevant insights that more accurately reflect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom